Gounder M et al. Nirogacestat, a y-secretase inhibitor for desmoid tumors. N Engl J Med 2023;388(10):898-912. Abstract

Gounder MM et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med 2018;379(25):2417-28. Abstract

Kasper B et al. Current management of desmoid tumors: A review. JAMA Oncol 2024;10(8):96-107. Abstract

Kasper B et al. Updated results of the RINGSIDE phase 2 trial and open-label extension of AL102 for treatment of desmoid tumors. ESMO 2024;Abstract 1766P.

Loggers ET et al. Monitoring ovarian function in oncology trials: Results and insights from the DeFi phase 3 trial of nirogacestat in desmoid tumors. ASCO 2024;Abstract 11520.

Mercier KA et al. Treatment landscape for desmoid tumors: Desmoid Tumor Research Foundation Natural History Study. ESMO Sarcoma and Rare Cancers 2024;Abstract 149P.

Stacchiotti S et al. Impact of nirogacestat on patient-reported outcomes in adults with desmoid tumor with a best overall response of stable disease: Post hoc analysis from the DeFi study. ESMO Sarcoma and Rare Cancers 2024;Abstract 57MO.

Toulmonde M et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumors (DESMOPAZ): A non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol 2018;20(9):1263-72. Abstract